JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Turner C. Lisle
Victor E. Laubach
Irving L. Kron
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lisle, T. C.
Right arrow Articles by Kron, I. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lisle, T. C.
Right arrow Articles by Kron, I. L.
Related Collections
Right arrow Lung - other
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation

J Thorac Cardiovasc Surg 2008;136:1280-1288
© 2008 The American Association for Thoracic Surgery


Cardiopulmonary Support and Physiology

Inflammatory lung injury after cardiopulmonary bypass is attenuated by adenosine A2A receptor activation

Turner C. Lisle, MDa,*, Leo M. Gazoni, MDa, Lucas G. Fernandez, MDa, Ashish K. Sharma, MBBSa, Andrew M. Bellizzi, MDb, Grant D. Schifflett, BAa, Victor E. Laubach, PhDa, Irving L. Kron, MDa

a Department of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Va
b Department of Pathology, University of Virginia, Charlottesville, Va

Received for publication April 28, 2008; revisions received June 6, 2008; accepted for publication July 5, 2008.

* Address for reprints: Turner C. Lisle, MD, University of Virginia Health System, Department of Surgery, PO Box 800679, Charlottesville, VA 22908. (Email: tl4b{at}virginia.edu).

Objective: Cardiopulmonary bypass has been shown to exert an inflammatory response within the lung, often resulting in postoperative pulmonary dysfunction. Several studies have shown that adenosine A2A receptor activation attenuates lung ischemia-reperfusion injury; however, the effect of adenosine A2A receptor activation on cardiopulmonary bypass-induced lung injury has not been studied. We hypothesized that specific adenosine A2A receptor activation by ATL313 would attenuate inflammatory lung injury after cardiopulmonary bypass.

Methods: Adult male Sprague-Dawley rats were randomly divided into 3 groups: 1) SHAM group (underwent cannulation + heparinization only); 2) CONTROL group (underwent 90 minutes of normothermic cardiopulmonary bypass with normal whole-blood priming solution; and 3) ATL group (underwent 90 minutes of normothermic cardiopulmonary bypass with ATL313 added to the normal priming solution).

Results: There was significantly less pulmonary edema and lung injury in the ATL group compared with the CONTROL group. The ATL group had significant reductions in bronchoalveolar lavage interleukin-1, interleukin-6, interferon-{gamma}, and myeloperoxidase levels compared with the CONTROL group. Similarly, lung tissue interleukin-6, tumor necrosis factor-{alpha}, and interferon-{gamma} were significantly decreased in the ATL group compared with the CONTROL group. There was no significant difference between the SHAM and ATL groups in the amount of pulmonary edema, lung injury, or levels of proinflammatory cytokines.

Conclusion: The addition of a potent adenosine A2A receptor agonist to the normal priming solution before the initiation of cardiopulmonary bypass significantly protects the lung from the inflammatory effects of cardiopulmonary bypass and reduces the amount of lung injury. Adenosine A2A receptor agonists could represent a new therapeutic strategy for reducing the potentially devastating consequences of the inflammatory response associated with cardiopulmonary bypass.



Abbreviations and Acronyms A2AR = adenosine A2A receptor; BAL = bronchoalveolar lavage; CPB = cardiopulmonary bypass; IFN = interferon; IL = interleukin; MPO = myeloperoxidase; TNF = tumor necrosis factor





This article has been cited by other articles:


Home page
PerfusionHome page
E Hirleman and D. Larson
Cardiopulmonary bypass and edema: physiology and pathophysiology
Perfusion, November 1, 2008; 23(6): 311 - 322.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.